BofA Securities upgraded Personalis from Neutral to Buy and set a new price target of $23.00 from $27.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2025 | $11.00 | Equal-Weight | Morgan Stanley |
| 5/15/2025 | $6.00 | Buy | Guggenheim |
| 3/17/2025 | $8.00 | Buy | Canaccord Genuity |
| 2/6/2023 | $8.00 | Hold → Buy | Needham |
| 2/6/2023 | Hold → Buy | Needham | |
| 2/25/2022 | $30.00 → $24.00 | Outperform | Oppenheimer |
| 2/25/2022 | $30.00 → $18.00 | Buy | Citigroup |
| 2/25/2022 | $50.00 → $38.00 | Buy | HC Wainwright & Co. |
Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth Expands Tempus’ reach across the cancer care continuum and accelerates access to industry-leading technology within the rapidly emerging MRD market, a $20 billion opportunity Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that it has entered into a definitive agreement to acquire Personalis, Inc. (NASDAQ:PSNL). The acquisition will expand Tempus' capabilities in minimal residual disease (MRD) and enhance its ab
Regulatory milestone for the NeXT Personal® Dx test enables clinical use of Personalis’ ultrasensitive MRD detection in Great BritainPersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that it has achieved UKCA (United Kingdom Conformity Assessed) marking for its NeXT Personal Dx test. This critical regulatory milestone enables the clinical use of Personalis’ ultrasensitive Minimal Residual Disease (MRD) detection technology across Great Britain, encompassing England, Wales, and Scotland.The UKCA marking confirms that the NeXT Personal Dx test meets the United Kingdom's stringent safety, health, and performance standards. This achievement dem
Regulatory milestone for specimen collection kits enables global deployment of Personalis' ultrasensitive MRD detection (Next Personal®) for drug development programs Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that its Personalis EDTA Blood Collection Kit and Personalis cfDNA Blood Collection Kit have obtained Class A CE-IVD marking in compliance with the European Union's In Vitro Diagnostic Regulation (IVDR). The CE Mark represents an important regulatory milestone, ensuring that clinical trial sites throughout the European Union and Great Britain can use these collection kits for interventional studies. These kits are specific
4 - Personalis, Inc. (0001527753) (Issuer)
4 - Personalis, Inc. (0001527753) (Issuer)
4 - Personalis, Inc. (0001527753) (Issuer)
4 - Personalis, Inc. (0001527753) (Issuer)
425 - Personalis, Inc. (0001527753) (Subject)
8-K - Personalis, Inc. (0001527753) (Filer)
425 - Personalis, Inc. (0001527753) (Subject)
Morgan Stanley resumed coverage of Personalis with a rating of Equal-Weight and set a new price target of $11.00
Guggenheim initiated coverage of Personalis with a rating of Buy and set a new price target of $6.00
Canaccord Genuity initiated coverage of Personalis with a rating of Buy and set a new price target of $8.00
SC 13G/A - Personalis, Inc. (0001527753) (Subject)
SC 13G - Personalis, Inc. (0001527753) (Subject)
SC 13D/A - Personalis, Inc. (0001527753) (Subject)
Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth Expands Tempus’ reach across the cancer care continuum and accelerates access to industry-leading technology within the rapidly emerging MRD market, a $20 billion opportunity Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that it has entered into a definitive agreement to acquire Personalis, Inc. (NASDAQ:PSNL). The acquisition will expand Tempus' capabilities in minimal residual disease (MRD) and enhance its ab
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2026 financial results on Thursday, May 7, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will
Dr. Chen expands his leadership role to serve as President while continuing to serve as Chief Medical Officer (CMO), unifying R&D innovation with operational execution as Personalis defines the next era of ultrasensitive MRD testing Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced the promotion of Richard Chen, M.D., M.S., to the position of President. Dr. Chen will continue to serve as CMO of Personalis in addition to his new role. The appointment comes at a critical inflection point as Personalis transitions from a pioneering R&D powerhouse into a market leader in Minimal Residual Disease (MRD) testing. Under Dr. Chen's scientific l
Bhandari to drive regulatory strategies for minimal residual disease (MRD) cancer test Personalis achieves ISO 13485:2016 certification, attesting to its ability to deliver medical devices and related services of the highest quality Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomic testing for precision oncology, today announced the appointment of Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance. With over two decades of industry marketing and regulatory affairs experience, Ms. Bhandari will help the company navigate the regulatory requirements for the NeXT Personal® MRD test. She was most recently VP, Regulatory Affairs at GRAIL, and previously held se
Personalis, Inc. (NASDAQ:PSNL) today announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors. Dr. Widder currently serves on the boards of QuidelOrtho Corporation and Evoke Pharma, Inc. and has over 40 years of experience working with biomedical companies, having previously served as a founder, director and/or CEO of Sydnexis, Inc., OrphoMed, Inc., Sytera, Inc., NovaCardia, Inc., Santarus, Inc., and Molecular Biosystems Inc., and as a general partner at LVP Life Science Ventures (formerly Latterell Venture Partners) and Windamere Venture Partners. He holds an M.D. from Northwestern University and trained in pathology at Duke University. "We are delighted to ha